http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 18 Sep 2024 06:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html <div class="xn-content"> <ul type="disc"><li>Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, <span value="ACORN:3614087564" idsrc="xmltag.org" >Actelion Pharmaceuticals</span>, Eisai, GSK, and the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> FDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that <person>Douglas B. Snyder</person>, joined the company as its Senior Vice President, General Counsel on <chron>September 18, 2024</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Appoints+Douglas+B.+Snyder+as+Senior+Vice+President%2C+General+Counsel/23734662.html Wed, 18 Sep 2024 06:00:00 -0400 A.06822034 A.09642568 A.11820776 A.35722072 A.36140875 A.39879666 A.41751660 ATLN GWPH IDYA O.00093063 O.00657442 O.06883669 O.20026344 O.20166571 O.20316942 O.20371933 O.28729778